Clinical outcomes and economic impact of the 2017 ACC/AHA guidelines on hypertension in China-Reference-Cited by-同舟云学术

Clinical outcomes and economic impact of the 2017 ACC/AHA guidelines on hypertension in China

Published:2019-07-03 Issue:8 Volume:21 Page:1212-1220
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J Clin Hypertens

Author:

Wang Zengwu¹^ORCID,Hao Guang²,Wang Xin¹,Chen Zuo¹,Zhang Linfeng¹,Zhang Zugui³,Hu Hao⁴,Weintraub William S.⁵,Gao Runlin⁶,

Affiliation:

1. Division of Prevention and Community Health, National Center for Cardiovascular Disease, National Clinical Research Center of Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital Peking Union Medical College & Chinese Academy of Medical Sciences Beijing China

2. Department of Epidemiology, School of Medicine Jinan University Guangzhou China

3. Christiana Care Health System Newark Delaware USA

4. China Health Technology Assessment Center, National Health Development Research Center National Health and Family Planning Commission Beijing China

5. MedStar Washington Hospital Center Washington District of Columbia USA

6. Department of Cardiology, Fuwai Hospital Peking Union Medical College & Chinese Academy of Medical Sciences Beijing China

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.13609

Reference29 articles.

1. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary

2. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

3. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial